Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 157

1.

N-homocysteinylation of tau and MAP1 is increased in autopsy specimens of Alzheimer's disease and vascular dementia.

Bossenmeyer-Pourié C, Smith AD, Lehmann S, Deramecourt V, Sablonnière B, Camadro JM, Pourié G, Kerek R, Helle D, Umoret R, Guéant-Rodriguez RM, Rigau V, Gabelle A, Sequeira JM, Quadros EV, Daval JL, Guéant JL.

J Pathol. 2019 Feb 8. doi: 10.1002/path.5254. [Epub ahead of print]

PMID:
30734924
2.

The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases.

Darlix A, Hirtz C, Thezenas S, Maceski A, Gabelle A, Lopez-Crapez E, De Forges H, Firmin N, Guiu S, Jacot W, Lehmann S.

BMC Cancer. 2019 Jan 30;19(1):110. doi: 10.1186/s12885-019-5287-z.

3.

Sample Pooling and Inflammation Linked to the False Selection of Biomarkers for Neurodegenerative Diseases in Top-Down Proteomics: A Pilot Study.

Molinari N, Roche S, Peoc'h K, Tiers L, Séveno M, Hirtz C, Lehmann S.

Front Mol Neurosci. 2018 Dec 18;11:477. doi: 10.3389/fnmol.2018.00477. eCollection 2018.

4.

Impact of CSF storage volume on the analysis of Alzheimer's disease biomarkers on an automated platform.

Delaby C, Muñoz L, Torres S, Nadal A, Le Bastard N, Lehmann S, Lleó A, Alcolea D.

Clin Chim Acta. 2019 Mar;490:98-101. doi: 10.1016/j.cca.2018.12.021. Epub 2018 Dec 20.

PMID:
30579960
5.

Cell-based therapy against prion diseases.

Relaño-Ginés A, Lehmann S, Crozet C.

Curr Opin Pharmacol. 2018 Nov 22;44:8-14. doi: 10.1016/j.coph.2018.11.001. [Epub ahead of print] Review.

PMID:
30472550
6.

Reduced brain amyloid burden in elderly patients with narcolepsy type 1.

Gabelle A, Jaussent I, Bouallègue FB, Lehmann S, Lopez R, Barateau L, Grasselli C, Pesenti C, de Verbizier D, Béziat S, Mariano-Goulart D, Carlander B, Dauvilliers Y; Alzheimer's Disease Neuroimaging Initiative; Multi-Domain Intervention Alzheimer's Prevention Trial study groups.

Ann Neurol. 2019 Jan;85(1):74-83. doi: 10.1002/ana.25373. Epub 2018 Dec 19.

PMID:
30387527
7.

Somatostatin and Neuropeptide Y in Cerebrospinal Fluid: Correlations With Amyloid Peptides Aβ1-42 and Tau Proteins in Elderly Patients With Mild Cognitive Impairment.

Duron E, Vidal JS, Grousselle D, Gabelle A, Lehmann S, Pasquier F, Buée L, Allinquant B, Schraen-Maschke S, Baret C, Rigaud AS, Hanon O, Epelbaum J.

Front Aging Neurosci. 2018 Oct 1;10:297. doi: 10.3389/fnagi.2018.00297. eCollection 2018.

8.

Interlaboratory validation of cerebrospinal fluid α-synuclein quantification in the diagnosis of sporadic Creutzfeldt-Jakob disease.

Kruse N, Heslegrave A, Gupta V, Foiani M, Villar-Piqué A, Schmitz M, Lehmann S, Teunissen C, Blennow K, Zetterberg H, Mollenhauer B, Zerr I, Llorens F.

Alzheimers Dement (Amst). 2018 Jul 7;10:461-470. doi: 10.1016/j.dadm.2018.06.005. eCollection 2018.

9.

Hepcidin: immunoanalytic characteristics.

Wolff F, de Verneuil H, Rucheton B, Lefebvre T, Vialaret J, Ropert-Bouchet M, Cunat S, Aguilar-Martinez P, Lehmann S, Delaby C.

Ann Biol Clin (Paris). 2018 Dec 1;76(6):705-715. doi: 10.1684/abc.2018.1382.

PMID:
30257815
10.

Impact of biological matrix on inflammatory protein biomarker quantification based on targeted mass spectrometry.

Incamps A, Saez-Boiteau C, Tiede SL, Rebillard P, Schulte J, Vialaret J, Beinrucker A, Lehmann S, Hirtz C.

Bioanalysis. 2018 Sep 1;10(17):1383-1399. doi: 10.4155/bio-2018-0149. Epub 2018 Sep 12.

PMID:
30207162
11.

Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.

Fortea J, Carmona-Iragui M, Benejam B, Fernández S, Videla L, Barroeta I, Alcolea D, Pegueroles J, Muñoz L, Belbin O, de Leon MJ, Maceski AM, Hirtz C, Clarimón J, Videla S, Delaby C, Lehmann S, Blesa R, Lleó A.

Lancet Neurol. 2018 Oct;17(10):860-869. doi: 10.1016/S1474-4422(18)30285-0. Epub 2018 Aug 29.

PMID:
30172624
12.

Alzheimer's Disease: Advances in Drug Development.

Piton M, Hirtz C, Desmetz C, Milhau J, Lajoix AD, Bennys K, Lehmann S, Gabelle A.

J Alzheimers Dis. 2018;65(1):3-13. doi: 10.3233/JAD-180145.

PMID:
30040716
13.

Cerebral Amyloid Angiopathy and Cerebral Amyloid Angiopathy-Related Inflammation: Comparison of Hemorrhagic and DWI MRI Features.

Renard D, Tatu L, Collombier L, Wacongne A, Ayrignac X, Charif M, Boukriche Y, Chiper L, Fourcade G, Azakri S, Gaillard N, Mercier E, Lehmann S, Thouvenot E.

J Alzheimers Dis. 2018;64(4):1113-1121. doi: 10.3233/JAD-180269.

PMID:
30010128
14.

Diagnosis of Methionine/Valine Variant Creutzfeldt-Jakob Disease by Protein Misfolding Cyclic Amplification.

Bougard D, Bélondrade M, Mayran C, Bruyère-Ostells L, Lehmann S, Fournier-Wirth C, Knight RS, Will RG, Green AJE.

Emerg Infect Dis. 2018 Jul;24(7):1364-1366. doi: 10.3201/eid2407.172105.

15.

Identification of multiple proteoforms biomarkers on clinical samples by routine Top-Down approaches.

Vialaret J, Schmit PO, Lehmann S, Gabelle A, Wood J, Bern M, Paape R, Suckau D, Kruppa G, Hirtz C.

Data Brief. 2018 Mar 31;18:1013-1021. doi: 10.1016/j.dib.2018.03.114. eCollection 2018 Jun.

16.

Relevance of Aβ42/40 Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLMR Scale.

Lehmann S, Delaby C, Boursier G, Catteau C, Ginestet N, Tiers L, Maceski A, Navucet S, Paquet C, Dumurgier J, Vanmechelen E, Vanderstichele H, Gabelle A.

Front Aging Neurosci. 2018 May 28;10:138. doi: 10.3389/fnagi.2018.00138. eCollection 2018.

17.

Regulatory context and validation of assays for clinical mass spectrometry proteomics (cMSP) methods.

Hirtz C, Bros P, Brede C, Lescuyer P, Maceski AM, Vialaret J, Delatour V, Lehmann S; IFCC Working Group on Clinical Quantitative Mass Spectrometry Proteomics (WG-cMSP).

Crit Rev Clin Lab Sci. 2018 Aug;55(5):346-358. doi: 10.1080/10408363.2018.1470159. Epub 2018 May 23.

PMID:
29792094
18.

What sample preparation should be chosen for targeted MS monoclonal antibody quantification in human serum?

Vialaret J, Broutin S, Pugnier C, Santelé S, Jaffuel A, Barnes A, Tiers L, Pelletier L, Lehmann S, Paci A, Hirtz C.

Bioanalysis. 2018 May 1;10(10):723-735. doi: 10.4155/bio-2018-0027. Epub 2018 May 17.

PMID:
29771137
19.

Nano-flow vs standard-flow: Which is the more suitable LC/MS method for quantifying hepcidin-25 in human serum in routine clinical settings?

Vialaret J, Picas A, Delaby C, Bros P, Lehmann S, Hirtz C.

J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Jun 1;1086:110-117. doi: 10.1016/j.jchromb.2018.04.003. Epub 2018 Apr 10.

PMID:
29660664
20.

Cerebrospinal fluid chitinase-3-like protein 1 level is not an independent predictive factor for the risk of clinical conversion in radiologically isolated syndrome.

Thouvenot E, Hinsinger G, Demattei C, Uygunoglu U, Castelnovo G, Pittion-Vouyovitch S, Okuda D, Kantarci O, Pelletier D, Lehmann S, Marin P, Siva A, Lebrun C; SFSEP and RISC.

Mult Scler. 2018 Mar 1:1352458518767043. doi: 10.1177/1352458518767043. [Epub ahead of print]

PMID:
29564952

Supplemental Content

Loading ...
Support Center